Press Releases Investors Overview News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts Company Info Overview Management Team Clinical Advisory Board Medical Consultants Presentations Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Investor Tools Email Alerts Tear Sheet Investor Presentation Contacts RSS News Feed News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 All Releases Financial Releases Viveve Reports Full Year 2019 Financial Results Mar 19, 2020 Viveve Announces Completion of VIVEVE II Pivotal FDA Clinical Trial for Improvement of Sexual Function Mar 12, 2020 Viveve to Host Conference Call to Provide Corporate Update and Year-End 2019 Financial Results on March 19, 2020 Mar 6, 2020 Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence Mar 4, 2020 Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence Jan 14, 2020 Viveve Announces Compliance with Nasdaq Listing Rules Dec 31, 2019 Viveve Announces Authorization to Initiate Short-Term Feasibility Study in Stress Urinary Incontinence from Canadian Ministry of Health Dec 18, 2019 Viveve Announces Clearance of Next Generation 2.0 System in South Korea Dec 10, 2019 Viveve Announces Launch of Viveve 2.0 System in China Dec 3, 2019 Viveve Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Nov 26, 2019 1 2 3 4 5 6 7 8 9 10 ...31
Viveve Announces Completion of VIVEVE II Pivotal FDA Clinical Trial for Improvement of Sexual Function Mar 12, 2020
Viveve to Host Conference Call to Provide Corporate Update and Year-End 2019 Financial Results on March 19, 2020 Mar 6, 2020
Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence Mar 4, 2020
Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence Jan 14, 2020
Viveve Announces Authorization to Initiate Short-Term Feasibility Study in Stress Urinary Incontinence from Canadian Ministry of Health Dec 18, 2019
Viveve Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Nov 26, 2019
